Last reviewed · How we verify
NS101 IV infusion — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
NS101 IV infusion (NS101 IV infusion) — Neuracle Science Co., LTD..
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| NS101 IV infusion TARGET | NS101 IV infusion | Neuracle Science Co., LTD. | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- NS101 IV infusion CI watch — RSS
- NS101 IV infusion CI watch — Atom
- NS101 IV infusion CI watch — JSON
- NS101 IV infusion alone — RSS
Cite this brief
Drug Landscape (2026). NS101 IV infusion — Competitive Intelligence Brief. https://druglandscape.com/ci/ns101-iv-infusion. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab